[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549328":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Karl Landsteiner University of Health Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cACLD",null,"Patients with compensated advanced chronic liver disease (cACLD) regardless of etiology",[13],"Diagnostic Test: hepatomiR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","hepatomiR","hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).",[9],[21],{"name":22,"affiliation":5,"role":23},"Andreas Maieron, PD Dr.","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Lukas Erhart, Mag. Dr.","CONTACT","00432742900412311","lukas.erhart@stpoelten.lknoe.at",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University Hospital St. Pölten","RECRUITING","Sankt Pölten","Lower Austria","3100","Austria","AT",{"type":40,"coordinates":41},"Point",[42,43],15.63725,48.20762,{"lat":43,"lon":42},[46],{"name":26,"role":27,"phone":10,"phoneExt":10,"email":29},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":6},"University Hospital St. Polten","100549328","hepatomir-cacld-study-100549328",false,"NCT06432582","hepatomiR cACLD Study","Assessment of a hepatomiR Cut-off for Predicting Specific Hepatic Decompensation Events in Advanced Chronic Liver Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Chronic liver disease (more than 6 months)\n* LSM ≥ 10 kPa\n* Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten\n* Signed patient consent form\n\nExclusion Criteria:\n\n* Age older than 18 years\n* Pregnancy\n* Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and\u002For extrahepatic spread","ALL","18 Years",{"count":62,"type":63},156,"ESTIMATED","OBSERVATIONAL","This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.",[67,68,69],"Chronic Liver Disease and Cirrhosis","Chronic Liver Disease","Portal Hypertension",[17,71,72,73],"micro-RNA","hepatic decompensation","ACLD","2025-09-08",{"date":76,"type":77},"2025-09-09","ACTUAL",{"date":79,"type":77},"2024-05-15",{"date":81,"type":63},"2026-06",{"name":5,"class":6},1]